Adjuvante medikamentöse Therapie des malignen Melanoms

Literatur

• 1 Balch C M, Maddox W A. The logic of adjunctive therapy in surgical patients with resectable cancer.  South Med J. 1978;  71 951-955
• 2 Barth A, Morton D L. The role of adjuvant therapy in melanoma management.  Cancer. 1995;  75 726-734
• 3 Bast RC J r, Zbar B, Borsos T, Rapp H J. BCG and cancer.  N Engl J Med. 1974;  290 1413-1420
• 4 Beiteke U, Ruppert P, Garbe C, Oxenfarth R, Kastl I, Türker T, Tronnier H, Frosch P J. Adjuvante Therapie des primären malignen Melanoms mit natürlichem humanen Interferon beta.  Hautarzt. 1993;  44 365-371
• 5 Cascinelli N, Bufalino R, Morabito A, MacKie R. Results of adjuvant interferon study in WHO melanoma programme.  Lancet. 1994;  343 913-914
• 6 Creagan E T, Cupps R E, Ivins J C, Pritchard D J, Sim F H, Soule E H, O¿Fallon J R. Adjuvant radiation therapy for regional nodal metastases from malignant melanoma: A randomized, prospective study.  Cancer. 1978;  42 2206-2210
• 7 Czarnetzki B M, Macher E, Suciu S, Thomas D, Steerenberg P A, Rümke P. Long-term adjuvant immunotherapy in stage I high risk malignant melanoma, comparing two BCG preparations versus non-treatment in a randomised multicentre study (EORTC Protocol 18781).  Eur J Cancer. 1993;  29A 1237-1242
• 8 Dummer R, Hauschild A, Henseler T, Burg G. Combined interferon-alpha and interleukin-2 adjuvant treatment for melanoma.  Lancet. 1998;  352 908-909
• 9 Eilber F R, Townsend C M jr, Morton D L. Results of BCG adjuvant immunotherapy for melanoma of the head and neck.  Am J Surg. 1976;  132 476-479
• 10 Goldie J H. Scientific basis for adjuvant and primary (neoadjuvant) chemotherapy.  Sem Oncol. 1987;  14 1-7
• 11 Grob J J, Dreno B, de la Salmoniere P, Delaunay M, Cupissol D, Guillot B, Souteyrand P, Sassolas B, Cesarini J P, Lionnet S, Lok C, Chastang C, Bonerandi J J. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker thatn 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma.  Lancet. 1998;  351 1905-1910
• 12 Häffner A C, Garbe C, Burg G, Büttner P, Orfanos C E, Rassner G. The prognosis of primary and metastaising melanoma. An evaluation of the TNM classification on 2.495 patients.  Br J Cancer. 1992;  66 856-861
• 13 Hauschild A, Sterry W. Adjuvante Therapie des malignen Melanoms.  Dtsch Med Wschr. 1992;  117 303-306
• 14 Hauschild A, Dummer R, Garbe C, Kaufmann R, Schadendorf D, Soyer H P, Stadler R, Tilgen W. Adjuvante Interferon-α-Therapie beim Melanom. Stellungnahme der Arbeitsgemeinschaft Dermatologische Onkologie (ADO).  Hautarzt. 1998;  49 167-169
• 15 Henz B M, Macher E, Bröcker E B, Suciu S, Steerenberg P A, Jung E, Rümke P. Prognostic value of tuberculin and BCG immunoreactivity in stage I high-risk malignant melanoma (EORTC protocol 18781).  Dermatology. 1996;  193 105-109
• 16 Hill G J, Moss S E, Golomb F M, Grage T B, Fletcher W S, Minton J P. et al . DTIC and combination therapy for melanoma, III: DTIC (NSC 45388) Surgical Adjuvant Study COG protocol 7040.  Cancer. 1981;  47 2556-2562
• 17 Kirkwood J M, Strawderman M H, Ernstoff M S, Smith T J, Borden E C, Blum R H. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684.  J Clin Oncol. 1996;  14 7-17
• 18 Kirkwood J, Agarwala S S. Adjuvant systemic therapy. In: Balch C. M., A. N. Houghton, A. J. Sober, soon Seng-jaw (eds.) Cutaneous melanoma Quality Medical Publishing, St. Louis 1998: 451-459
• 19 Komission klinische Studien der ADO . Aktuelle Stellungnahme der Arbeitsgemeinschaft Dermatologische Onkologie zur Hochdosistherapie mit Interferon α2b.  Hautarzt. 1999;  50 395-397
• 20 Koops H S, Vaglini M, Suciu S, Kroon B B, Thompson J F, Gohl J, Eggermont A M, Di Filippo F, Krementz E T, Ruiter D, Lejeune F J. Prophylactic isolated limb perfusio for localized, high-risk limb melanoma: Results of a multicenter randomized phase III trial. European Organization for Research and Treamtent of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, and the North American Perfusion Group Southwest Oncology Group-8593.  J Clin Oncol. 1998;  16 2906-2912
• 21 Lipton A, Harvey H A, Balch C M, Antle C E, Heckard R, Bartolucci A A. Corynebacterium parvum versus bacille Calmette-Guérin adjuvant immunotherapy of stage II malignant melanoma.  J Clin Oncol. 1991;  9 1151-1156
• 22 Livingston P O, Wong G Y, Adluri S, Tao Y, Padavan M, Parente R, Hanlon C, Calves M J, Helling F, Ritter G. et al . Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside.  J Clin Oncol. 1994;  12 1036-1044
• 23 Meisenberg B R, Ross M, Vredenburgh J J, Jones R, Sphall E J, Seigler H F, Coniglio D M, Wu K, Peters W P. Randomized trial of high-dose chemotherapy with autologous bone marrow support as adjuvant therapy for high-risk, multi-node-positive malignant melanoma.  J Natl Cancer Inst. 1993;  85 1080-1085
• 24 Meyskens F L, Kopecky K, Samson M, Hersh E, MacDonald J, Jaffe H. et al . Recombinant human interferon gamma: Adverse effects in high-risk stage I and II cutaneous malignant melanoma.  J Natl Cancer Inst. 1990;  82 1071
• 25 Morton D L, Eilber F R, Malmgren R A, Wood W C. Immunological factors which influence response to immunotherapy in malignant melanoma.  Surgery. 1970;  68 158-163
• 26 Nestle F O, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.  Nat Med. 1998;  4 328-332
• 27 Pehamberger H, Soyer H P, Steiner A, Kofler R, Binder M, Mischer P, Pachinger W, Auboeck J, Fritsch P, Kerl H, Wolff K. Adjuvant interferon-α2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group.  J Clin Oncol. 1998;  16 1425-1429
• 28 Retsas S, Quigley M, Pectasides D, Macrae K, Henry K. Clinical and histologic involvement of regional lymph nodes in malignant melanoma.  Cancer. 1994;  73 2119-2130
• 29 Richards J M. Sequential chemoimmunotherapy for metastatic melanoma.  Semin Oncol. 1991;  18 91-95
• 30 Schabel F M jr. Concepts for systemic treatment of micrometastases.  Cancer. 1975;  35 15-24
• 31 Tilgen W. Therapie des malignen Melanoms: Derzeitiger Stand und Perspektiven. In: Jahrbuch der Dermatologie. Macher E, Kolde G, Bröcker EB (Hrsg.) Biermann, Zülpich 1995: 123-150
• 32 Veronesi U, Adamus J, Aubert C, Bajetta E, Beretta G, Bonadonna G. et al . A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma.  N Engl J Med. 1982;  307 913-916
• 33 Volkenandt M, Schmidt M, Konz B, Gummer M, Hein R, Plewig G, Hölzel D. Klinisch-epidemiologische Daten von Patienten mit malignen Melanomen aus dem Bereich des Tumorzentrums München von 1977 bis 1997.  Hautarzt. 1999;  50 470-478

Korrespondenz